Shiela Subramanian
Internal Medicine · New Cauaan, CTNPI 1538235163
Payments from drug & device makers
Across 49 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$160
- Merck$105
- Boehringer Ingelheim$103
- Myriad Women's Health, Inc.$90
- AstraZeneca$82
- Novo Nordisk$75
- plus $455 from 15 others
What the payments were for
- Food & beverage$1,068100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 7 | $160 |
| Merck | 5 | $105 |
| Boehringer Ingelheim | 5 | $103 |
| Myriad Women's Health, Inc. | 1 | $90 |
| AstraZeneca | 5 | $82 |
| Novo Nordisk | 3 | $75 |
| Lilly USA, LLC | 3 | $66 |
| Amgen | 3 | $63 |
| Baxter Healthcare | 1 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| AbbVie | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Johnson & Johnson | 2 | $27 |
| Kaleo, Inc. | 1 | $21 |
| Intra-sana Laboratories | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Pfizer | 1 | $13 |
How this compares
$1,068 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $29,999 |
| Dexlansoprazole DrDexlansoprazole | 13 | $2,517 |
| SynthroidLevothyroxine Sodium | 18 | $1,639 |
| Celecoxib | 36 | $1,092 |
| Rosuvastatin Calcium | 56 | $1,074 |
| Levothyroxine Sodium | 76 | $995 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $820 |
| Liothyronine Sodium | 12 | $785 |
| Atorvastatin Calcium | 71 | $776 |
| Gabapentin | 30 | $695 |
| Pantoprazole Sodium | 27 | $573 |
| Losartan Potassium | 41 | $536 |
| Zolpidem Tartrate ErZolpidem Tartrate | 18 | $509 |
| Metformin Hcl | 39 | $499 |
| Nifedipine ErNifedipine | 15 | $495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $29,99927 claims |
| AbbVieSynthroid | $39 | $1,63918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in New Cauaan
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.